Ken Griffin Crinetics Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 884,507 shares of CRNX stock, worth $38.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

884,507

Previous 653,635 35.32%

Holding current value

$38.5 Million

Previous $18.8 Million 95.97%

% of portfolio

0.01%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$26.85 - $45.91 $6.2 Million - $10.6 Million	230,872 Added 35.32%	884,507 $36.8 Million
Q2 2025 Aug 14, 2025	BUY	$25.56 - $33.76 $15.7 Million - $20.8 Million	615,084 Added 1595.51%	653,635 $18.8 Million
Q1 2025 May 15, 2025	BUY	$32.3 - $53.15 $1.09 Million - $1.8 Million	33,829 Added 716.41%	38,551 $1.29 Million
Q4 2024 Feb 14, 2025	SELL	$50.66 - $60.69 $6.61 Million - $7.91 Million	-130,412 Reduced 96.51%	4,722 $241,000
Q3 2024 Nov 14, 2024	BUY	$43.83 - $54.98 $580,966 - $728,759	13,255 Added 10.88%	135,134 $6.9 Million

Q2 2024 Aug 14, 2024	SELL	$42.12 - $51.91 $2.09 Million - $2.57 Million	-49,545 Reduced 28.9%	121,879 $5.46 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $5.17 Million - $6.96 Million	148,632 Added 652.12%	171,424 $8.02 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $3.5 Million - $5.06 Million	-136,444 Reduced 85.69%	22,792 $810,000
Q3 2023 Nov 14, 2023	SELL	$15.97 - $30.59 $1.32 Million - $2.52 Million	-82,492 Reduced 34.13%	159,236 $4.74 Million
Q2 2023 Aug 14, 2023	SELL	$15.73 - $23.6 $690,027 - $1.04 Million	-43,867 Reduced 15.36%	241,728 $4.36 Million
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $3.8 Million - $5.24 Million	248,239 Added 664.52%	285,595 $4.59 Million
Q4 2022 Feb 14, 2023	SELL	$15.49 - $19.05 $44,223 - $54,387	-2,855 Reduced 7.1%	37,356 $683,000
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $728,221 - $899,520	40,211 New	40,211 $790,000
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $256,992 - $424,225	-14,985 Reduced 23.12%	49,839 $1.09 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $534,156 - $784,258	27,605 Added 74.17%	64,824 $1.84 Million
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $395,650 - $591,365	-23,439 Reduced 38.64%	37,219 $783,000
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $964,462 - $1.28 Million	60,658 New	60,658 $1.14 Million
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $623,291 - $822,463	-46,864 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $93,764 - $135,524	7,762 Added 19.85%	46,864 $661,000
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $82,755 - $107,302	6,076 Added 18.4%	39,102 $613,000
Q2 2020 Aug 14, 2020	SELL	$13.04 - $23.23 $35,351 - $62,976	-2,711 Reduced 7.59%	33,026 $579,000
Q1 2020 May 15, 2020	BUY	$11.52 - $26.46 $89,959 - $206,626	7,809 Added 27.96%	35,737 $526,000
Q4 2019 Feb 14, 2020	BUY	$15.24 - $25.09 $4,495 - $7,401	295 Added 1.07%	27,928 $701,000
Q3 2019 Nov 14, 2019	BUY	$14.91 - $25.01 $236,159 - $396,133	15,839 Added 134.3%	27,633 $415,000
Q2 2019 Aug 14, 2019	BUY	$21.48 - $27.71 $253,335 - $326,811	11,794 New	11,794 $295,000

Others Institutions Holding CRNX

# of Institutions

246

Shares Held

92.8M

Call Options Held

1.02M

Put Options Held

204K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.34B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account